Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 314.17 g/mol |
|---|---|
| Molecular Formula | C9H17Cl2N5O3 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 2 |
| Exact Mass | 313.0708448 g/mol |
| Monoisotopic Mass | 313.0708448 g/mol |
| Topological Polar Surface Area | 132 A^2 |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 405 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-10-18
Pay. Date : 2021-09-28
DMF Number : 36147
Submission : 2021-07-31
Status : Active
Type : II
Date of Issue : 2025-02-27
Valid Till : 2028-02-26
Written Confirmation Number : WC-0511
Address of the Firm :
NDC Package Code : 73435-017
Start Marketing Date : 2021-12-06
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-09-20
Pay. Date : 2019-07-26
DMF Number : 33928
Submission : 2019-08-06
Status : Active
Type : II
Date of Issue : 2025-09-03
Valid Till : 2028-09-02
Written Confirmation Number : WC-0362
Address of the Firm :
NDC Package Code : 69037-0048
Start Marketing Date : 2013-12-19
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : ASMF, CN |
GDUFA
DMF Review : Reviewed
Rev. Date : 2025-11-13
Pay. Date : 2025-09-30
DMF Number : 41077
Submission : 2024-12-31
Status : Active
Type : II
Date of Issue : 2024-02-12
Valid Till : 2027-02-11
Written Confirmation Number : WC-0407
Address of the Firm :
NDC Package Code : 70600-062
Start Marketing Date : 2024-11-14
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28416
Submission : 2014-06-20
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2014-03-04
Pay. Date : 2013-09-23
DMF Number : 26682
Submission : 2012-12-06
Status : Active
Type : II
NDC Package Code : 46438-0664
Start Marketing Date : 2021-12-17
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2020-06-23
Pay. Date : 2019-03-22
DMF Number : 33553
Submission : 2019-02-19
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2020-03-13
Pay. Date : 2019-12-13
DMF Number : 34185
Submission : 2019-10-03
Status : Active
Type : II
Date of Issue : 2022-04-08
Valid Till : 2024-11-01
Written Confirmation Number : WC-0290A3
Address of the Firm :
NDC Package Code : 72643-026
Start Marketing Date : 2021-09-21
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42146
Submission : 2025-07-17
Status : Active
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-08-26
Pay. Date : 2020-06-15
DMF Number : 34926
Submission : 2020-06-17
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Related Excipient Companies
Excipients by Applications
Global Sales Information
Main Therapeutic Indication : Nephrology
Currency : USD
2020 Revenue in Millions : 458
2019 Revenue in Millions : 463
Growth (%) : -1

Main Therapeutic Indication : Nephrology
Currency : USD
2021 Revenue in Millions : 286
2020 Revenue in Millions : 458
Growth (%) : -38

Main Therapeutic Indication : Genetic Diseases
Currency : USD
2022 Revenue in Millions : 228
2021 Revenue in Millions : 286
Growth (%) : -20

Main Therapeutic Indication : Genetic Diseases
Currency : USD
2023 Revenue in Millions : 181
2022 Revenue in Millions : 228
Growth (%) : -21

Main Therapeutic Indication : Genetic Diseases
Currency : USD
2024 Revenue in Millions : 121
2023 Revenue in Millions : 181
Growth (%) : -33

Main Therapeutic Indication : Hyperphenylalaninemia
Currency : USD
2017 Revenue in Millions : 408
2016 Revenue in Millions : 348
Growth (%) : 17

Main Therapeutic Indication : Renal Disorders
Currency : USD
2018 Revenue in Millions : 434
2017 Revenue in Millions : 408
Growth (%) : 6%

Main Therapeutic Indication : Nephrology
Currency : USD
2019 Revenue in Millions : 463
2018 Revenue in Millions : 434
Growth (%) : 7

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
10 Apr 2026
Reply
30 Jan 2025
Reply
29 Oct 2024
Reply
20 Oct 2023
Reply
22 Jun 2022
Reply
03 Dec 2021
Reply
14 Jan 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
89
PharmaCompass offers a list of Sapropterin Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Sapropterin Hydrochloride manufacturer or Sapropterin Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sapropterin Hydrochloride manufacturer or Sapropterin Hydrochloride supplier.
A Kuvan (TN) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Kuvan (TN), including repackagers and relabelers. The FDA regulates Kuvan (TN) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Kuvan (TN) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Kuvan (TN) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Kuvan (TN) supplier is an individual or a company that provides Kuvan (TN) active pharmaceutical ingredient (API) or Kuvan (TN) finished formulations upon request. The Kuvan (TN) suppliers may include Kuvan (TN) API manufacturers, exporters, distributors and traders.
click here to find a list of Kuvan (TN) suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Kuvan (TN) DMF (Drug Master File) is a document detailing the whole manufacturing process of Kuvan (TN) active pharmaceutical ingredient (API) in detail. Different forms of Kuvan (TN) DMFs exist exist since differing nations have different regulations, such as Kuvan (TN) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Kuvan (TN) DMF submitted to regulatory agencies in the US is known as a USDMF. Kuvan (TN) USDMF includes data on Kuvan (TN)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Kuvan (TN) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Kuvan (TN) suppliers with USDMF on PharmaCompass.
A Kuvan (TN) written confirmation (Kuvan (TN) WC) is an official document issued by a regulatory agency to a Kuvan (TN) manufacturer, verifying that the manufacturing facility of a Kuvan (TN) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Kuvan (TN) APIs or Kuvan (TN) finished pharmaceutical products to another nation, regulatory agencies frequently require a Kuvan (TN) WC (written confirmation) as part of the regulatory process.
click here to find a list of Kuvan (TN) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Kuvan (TN) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Kuvan (TN) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Kuvan (TN) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Kuvan (TN) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Kuvan (TN) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Kuvan (TN) suppliers with NDC on PharmaCompass.
Kuvan (TN) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Kuvan (TN) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Kuvan (TN) GMP manufacturer or Kuvan (TN) GMP API supplier for your needs.
A Kuvan (TN) CoA (Certificate of Analysis) is a formal document that attests to Kuvan (TN)'s compliance with Kuvan (TN) specifications and serves as a tool for batch-level quality control.
Kuvan (TN) CoA mostly includes findings from lab analyses of a specific batch. For each Kuvan (TN) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Kuvan (TN) may be tested according to a variety of international standards, such as European Pharmacopoeia (Kuvan (TN) EP), Kuvan (TN) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Kuvan (TN) USP).